List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4191096/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Detection of Prostate Cancer Using Biparametric Prostate <scp>MRI</scp> , Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. Journal of Magnetic Resonance Imaging, 2022, 55, 465-477.	1.9	9
2	Diagnostic potential of nanoparticle aided assays for <scp>MUC16</scp> and <scp>MUC1</scp> glycovariants in ovarian cancer. International Journal of Cancer, 2022, 151, 1175-1184.	2.3	6
3	Prospective validation of microseminoproteinâ€Ĵ² added to the 4Kscore in predicting highâ€grade prostate cancer in an international multicentre cohort. BJU International, 2021, 128, 218-224.	1.3	3
4	Three two-site apoA-I immunoassays using phage expressed detector antibodies – Preliminary clinical evaluation with cardiac patients. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113772.	1.4	1
5	Upconverting nanoparticle reporter–based highly sensitive rapid lateral flow immunoassay for hepatitis B virus surface antigen. Analytical and Bioanalytical Chemistry, 2021, 413, 967-978.	1.9	25
6	Double-Antigen Lateral Flow Immunoassay for the Detection of Anti-HIV-1 and -2 Antibodies Using Upconverting Nanoparticle Reporters. Sensors, 2021, 21, 330.	2.1	18
7	Sensitive and quantitative detection of cardiac troponin I with upconverting nanoparticle lateral flow test with minimized interference. Scientific Reports, 2021, 11, 18698.	1.6	16
8	Detection of bladder cancer with aberrantly fucosylated ITGA3. Analytical Biochemistry, 2021, 628, 114283.	1.1	9
9	Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machineâ€Learning Techniques. Journal of Magnetic Resonance Imaging, 2020, 51, 1540-1553.	1.9	3
10	A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer. Gynecologic Oncology, 2020, 156, 689-694.	0.6	16
11	Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results. Molecular Aspects of Medicine, 2020, 72, 100831.	2.7	9
12	HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma. Acta Oncológica, 2020, 59, 1461-1468.	0.8	11
13	Ultrasensitive and Robust Point-of-Care Immunoassay for the Detection of <i>Plasmodium falciparum</i> Malaria. Analytical Chemistry, 2020, 92, 15766-15772.	3.2	11
14	Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125. Communications Biology, 2020, 3, 460.	2.0	23
15	Evaluation of a New Skeletal Troponin I Assay in Patients with Idiopathic Inflammatory Myopathies. journal of applied laboratory medicine, The, 2020, 5, 320-331.	0.6	1
16	Exploratory Analysis of CA125-MGL and –STn Glycoforms in the Differential Diagnostics of Pelvic Masses. journal of applied laboratory medicine, The, 2020, 5, 263-272.	0.6	9
17	Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB. Human Molecular Genetics, 2020, 29, 1581-1591.	1.4	8
18	Cardiac troponin elevations in marathon runners. Role of coronary atherosclerosis and skeletal muscle injury. The MaraCat Study. International Journal of Cardiology, 2019, 295, 25-28.	0.8	19

#	Article	IF	CITATIONS
19	A Nanoparticle-Based Approach for the Detection of Extracellular Vesicles. Scientific Reports, 2019, 9, 10038.	1.6	30
20	Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma. PLoS ONE, 2019, 14, e0219480.	1.1	26
21	Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer–Associated CA125 from Benign Sources. journal of applied laboratory medicine, The, 2019, 4, 299-310.	0.6	12
22	Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free Prostate-Specific Antigen. journal of applied laboratory medicine, The, 2019, 3, 1014-1021.	0.6	0
23	Free PAPP-A as a biomarker: heparin-induced release is not related to coronary atherosclerotic burden. Clinical Chemistry and Laboratory Medicine, 2019, 57, e155-e158.	1.4	0
24	High-sensitivity lateral flow immunoassay with a fluorescent lanthanide nanoparticle label. Journal of Immunological Methods, 2019, 465, 39-44.	0.6	29
25	Microparticleâ^'based platform for point-of-care immunoassays. Analytical Biochemistry, 2018, 548, 66-68.	1.1	3
26	Direct Immunoassay for Free Pregnancy-Associated Plasma Protein A (PAPP-A). journal of applied laboratory medicine, The, 2018, 3, 438-449.	0.6	4
27	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. European Journal of Epidemiology, 2017, 32, 521-527.	2.5	36
28	Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection. Clinical Biochemistry, 2017, 50, 54-61.	0.8	24
29	Potentially pathogenic circulating autoantibodies to cardiac troponin are present in hemodialysis patients. Hemodialysis International, 2017, 21, 519-523.	0.4	1
30	Lateral flow immunoassay with upconverting nanoparticleâ€based detection for indirect measurement of interferon response by the level of MxA. Journal of Medical Virology, 2017, 89, 598-605.	2.5	22
31	Role of lectin microarrays in cancer diagnosis. Proteomics, 2016, 16, 1257-1265.	1.3	68
32	Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections. Journal of Histochemistry and Cytochemistry, 2016, 64, 311-322.	1.3	0
33	A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources. Clinical Chemistry, 2016, 62, 1390-1400.	1.5	21
34	Stratification of aggressive prostate cancer from indolent disease—Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 255.e15-255.e22.	0.8	8
35	Global expression of AMACR transcripts predicts risk for prostate cancer – a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. BMC Urology, 2016, 16, 10.	0.6	19
36	Europium nanoparticle-based simple to perform dry-reagent immunoassay for the detection of hepatitis B surface antigen. Journal of Virological Methods, 2016, 229, 66-69.	1.0	5

#	Article	IF	CITATIONS
37	Anti-HCV immunoassays based on a multiepitope antigen and fluorescent lanthanide chelate reporters. Journal of Virological Methods, 2016, 228, 67-73.	1.0	9
38	ldentification and analysis of anti-HDL scFv-antibodies obtained from phage display based synthetic antibody library. Clinical Biochemistry, 2016, 49, 472-479.	0.8	8
39	Array-in-well platform–based multiplex assay for the simultaneous detection of anti-HIV- and treponemal-antibodies, and Hepatitis B surface antigen. Journal of Immunological Methods, 2016, 429, 21-27.	0.6	7
40	Effects of blood sample anticoagulants on lateral flow assays using luminescent photon-upconverting and Eu(III) nanoparticle reporters. Analytical Biochemistry, 2016, 492, 13-20.	1.1	31
41	Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. PLoS ONE, 2016, 11, e0155901.	1.1	43
42	All-in-one dry-reagent time-resolved immunofluorometric assay for the rapid detection of HIV-1 and -2 infections. Journal of Virological Methods, 2015, 226, 52-59.	1.0	5
43	Elevation of cardiac troponins measured after recreational resistance training. Clinical Biochemistry, 2015, 48, 803-806.	0.8	16
44	Skeletal troponin I cross-reactivity in different cardiac troponin I assay versions. Clinical Biochemistry, 2015, 48, 313-317.	0.8	12
45	Phage display aided improvement of a unique prostate-specific antigen (PSA) antibody unreactive with Lys145–Lys146 internally cleaved forms. Journal of Immunological Methods, 2015, 422, 72-79.	0.6	3
46	Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates. BMC Urology, 2015, 15, 88.	0.6	6
47	Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case–Control Study. European Urology, 2015, 68, 207-213.	0.9	120
48	Chimeric recombinant antibody fragments in cardiac troponin I immunoassay. Clinical Biochemistry, 2015, 48, 347-352.	0.8	4
49	Autoantibody prevalence with an improved immunoassay for detecting cardiac troponin-specific autoantibodies. Clinical Chemistry and Laboratory Medicine, 2014, 52, 273-9.	1.4	15
50	Extension of dynamic range of sensitive nanoparticle-based immunoassays. Analytical Biochemistry, 2014, 446, 82-86.	1.1	4
51	Novel sensitive cardiac troponin I immunoassay free from troponin I-specific autoantibody interference. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1041-8.	1.4	8
52	Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens. Urology, 2014, 83, 511.e1-511.e7.	0.5	15
53	Epitope Specificity and IgG Subclass Distribution of Autoantibodies to Cardiac Troponin. Clinical Chemistry, 2013, 59, 512-518.	1.5	23
54	A comparison of capture antibody fragments in cardiac troponin I immunoassay. Clinical Biochemistry, 2013, 46, 963-968.	0.8	22

#	Article	IF	CITATIONS
55	Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. Clinical Biochemistry, 2013, 46, 670-674.	0.8	11
56	Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations. Journal of the National Cancer Institute, 2013, 105, 237-243.	3.0	42
57	Can one blood draw replace transrectal ultrasonographyâ€estimated prostate volume to predict prostate cancer risk?. BJU International, 2013, 112, 602-609.	1.3	10
58	Europium Nanoparticle-Based High Performing Immunoassay for the Screening of Treponemal Antibodies. PLoS ONE, 2013, 8, e84050.	1.1	5
59	Troponin-Specific Autoantibody Interference in Different Cardiac Troponin I Assay Configurations. Clinical Chemistry, 2012, 58, 1040-1048.	1.5	35
60	Rapid and sensitive cardiac troponin I immunoassay based on fluorescent europium(III)-chelate-dyed nanoparticles. Clinica Chimica Acta, 2012, 414, 70-75.	0.5	33
61	Performance of fluorescent europium(III) nanoparticles and colloidal gold reporters in lateral flow bioaffinity assay. Analytical Biochemistry, 2012, 428, 31-38.	1.1	100
62	Intact and Internally Cleaved Free Prostate-Specific Antigen in Patients With Prostate Cancer With Different Pathologic Stages and Grades. Urology, 2011, 77, 1009.e1-1009.e8.	0.5	10
63	Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys145 or Lys146 from fPSA without internal cleavages at Lys145 or Lys146. Journal of Immunological Methods, 2011, 369, 74-80.	0.6	10
64	Simultaneous detection of Human Immunodeficiency Virus 1 and Hepatitis B virus infections using a dual-label time-resolved fluorometric assay. Journal of Nanobiotechnology, 2010, 8, 27.	4.2	15
65	Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication. Journal of Clinical Oncology, 2010, 28, 2493-2498.	0.8	204
66	Autoantibodies to cardiac troponin in acute coronary syndromes. Clinica Chimica Acta, 2010, 411, 1793-1798.	0.5	21
67	Autoantibodies to Cardiac Troponin Associate with Higher Initial Concentrations and Longer Release of Troponin I in Acute Coronary Syndrome Patients. Clinical Chemistry, 2009, 55, 938-945.	1.5	52
68	Quantitative real-time RT-PCR assay for PCA3. Clinical Biochemistry, 2008, 41, 103-108.	0.8	34
69	A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in GA¶teborg, Sweden. BMC Medicine, 2008, 6, 19.	2.3	212
70	Clinical Significance of Troponin I Efflux and Troponin Autoantibodies in Patients With Dilated Cardiomyopathy. Journal of Cardiac Failure, 2008, 14, 481-488.	0.7	35
71	Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood. Clinical Biochemistry, 2007, 40, 111-118.	0.8	11
72	Intact Free Prostate-Specific Antigen and Free and Total Human Glandular KallikreinÂ2. Elimination of Assay Interference by Enzymatic Digestion of Antibodies to F(abâ€~)2Fragments. Analytical Chemistry, 2006, 78, 7809-7815.	3.2	61

#	Article	IF	CITATIONS
73	Associations Between Homocysteine, Bone Turnover, BMD, Mortality, and Fracture Risk in Elderly Women. Journal of Bone and Mineral Research, 2006, 22, 127-134.	3.1	103
74	Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate, 2005, 63, 13-18.	1.2	35
75	Negative Interference in Cardiac Troponin I Immunoassays by Circulating Troponin Autoantibodies. Clinical Chemistry, 2005, 51, 839-847.	1.5	116
76	Autoantibodies against Cardiac Troponins. New England Journal of Medicine, 2005, 352, 98-100.	13.9	79
77	Comparison of Cardiac Troponin I Immunoassays Variably Affected by Circulating Autoantibodies. Clinical Chemistry, 2005, 51, 848-855.	1.5	54
78	Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone, 2005, 36, 786-792.	1.4	53
79	Development of Sensitive Immunoassays for Free and Total Human Glandular Kallikrein 2. Clinical Chemistry, 2004, 50, 1607-1617.	1.5	47
80	An interfering component in cardiac troponin l immunoassays—lts nature and inhibiting effect on the binding of antibodies against different epitopes. Clinical Biochemistry, 2004, 37, 472-480.	0.8	33
81	Identification of novel proteolytic forms of osteocalcin in human urine. Biochemical and Biophysical Research Communications, 2003, 306, 973-980.	1.0	25
82	Negative Interference in Cardiac Troponin I Immunoassays from a Frequently Occurring Serum and Plasma Component. Clinical Chemistry, 2003, 49, 1095-1104.	1.5	92
83	Discrimination of Benign From Malignant Prostatic Disease by Selective Measurements of Single Chain, Intact Free Prostate Specific Antigen. Journal of Urology, 2002, 168, 1917-1922.	0.2	46
84	Simultaneous Quantification of Prostate-specific Antigen and Human Glandular Kallikrein 2 mRNA in Blood Samples from Patients with Prostate Cancer and Benign Disease. Clinical Chemistry, 2002, 48, 1265-1271.	1.5	14
85	Point-of-Care Time-resolved Immunofluorometric Assay for Human Pregnancy-associated Plasma Protein A: Use in First-Trimester Screening for Down Syndrome. Clinical Chemistry, 2002, 48, 473-483.	1.5	29
86	Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. Journal of Urology, 2002, 168, 1917-22.	0.2	12
87	Development of Highly Fluorescent Detection Reagents for the Construction of Ultrasensitive Immunoassays. Analytical Chemistry, 2001, 73, 1521-1529.	3.2	38
88	Measurement of Circulating Forms of Prostate-specific Antigen in Whole Blood Immediately after Venipuncture: Implications for Point-of-Care Testing. Clinical Chemistry, 2001, 47, 703-711.	1.5	10
89	Discrimination of Prostate Cancer from Benign Disease by Plasma Measurement of Intact, Free Prostate-specific Antigen Lacking an Internal Cleavage Site at Lys145-Lys146. Clinical Chemistry, 2001, 47, 1415-1423.	1.5	82
90	Sensitive LH and FSH assays for monitoring low serum levels in men undergoing steroidal contraception. Clinical Endocrinology, 2001, 55, 331-339.	1.2	18

KIM PETTERSSON

#	Article	IF	CITATIONS
91	Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate, 2001, 49, 101-109.	1.2	82
92	Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction. Basic Research in Cardiology, 2000, 95, 413-417.	2.5	22
93	Production and Characterization of Novel Anti-Prostate-specific Antigen (PSA) Monoclonal Antibodies That Do Not Detect Internally Cleaved Lys145-Lys146 Inactive PSA. Clinical Chemistry, 2000, 46, 1610-1618.	1.5	60
94	Development and Evaluation of Three Immunofluorometric Assays That Measure Different Forms of Osteocalcin in Serum. Clinical Chemistry, 2000, 46, 332-337.	1.5	50
95	Dual-Label Time-resolved Immunofluorometric Assay of Free and Total Prostate-specific Antigen Based on Recombinant Fab Fragments. Clinical Chemistry, 2000, 46, 658-666.	1.5	59
96	Sensitive and Specific Immunodetection of Human Glandular Kallikrein 2 in Serum. Clinical Chemistry, 2000, 46, 198-206.	1.5	58
97	Combined Inhibin and CA125 Assays in the Detection of Ovarian Cancer. Clinical Chemistry, 1999, 45, 651-658.	1.5	55
98	Time-resolved fluorescence in immunocytochemical detection of prostate-specific antigen in prostatic tissue sections. The Histochemical Journal, 1999, 31, 45-52.	0.6	21
99	Demonstration of the Predominant Urine Osteocalcin Fragments Detectable by Two-Site Immunoassays. Journal of Bone and Mineral Research, 1999, 14, 431-438.	3.1	12
100	Two-Site Immunoassays for Osteoclastic Tartrate-Resistant Acid Phosphatase Based on Characterization of Six Monoclonal Antibodies. Journal of Bone and Mineral Research, 1999, 14, 464-469.	3.1	42
101	The Proportion of Carboxylated to Total or Intact Osteocalcin in Serum Discriminates Warfarin-Treated Patients from Control Subjects. Journal of Bone and Mineral Research, 1999, 14, 555-560.	3.1	23
102	Characterization of Serum Tartrate-Resistant Acid Phosphatase and Development of a Direct Two-Site Immunoassay. Journal of Bone and Mineral Research, 1998, 13, 683-687.	3.1	55
103	A Dual-Label Immunofluorometric Assay for Human Osteocalcin. Journal of Bone and Mineral Research, 1998, 13, 1183-1190.	3.1	6
104	The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. , 1998, 83, 2540-2547.		41
105	Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. Protein Science, 1998, 7, 259-269.	3.1	60
106	Determination of a common genetic variant of luteinizing hormone using DNA hybridization and immunoassays. Clinical Endocrinology, 1998, 49, 369-376.	1.2	47
107	The Frequency of an Inactivating Point Mutation (566C→T) of the Human Follicle-Stimulating Hormone Receptor Gene in Four Populations Using Allele-Specific Hybridization and Time-Resolved Fluorometry1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4338-4343.	1.8	60
108	Degradation of cardiac troponin I: implication for reliable immunodetection. Clinical Chemistry, 1998, 44, 2433-2440.	1.5	215

#	Article	IF	CITATIONS
109	The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer, 1998, 83, 2540-2547.	2.0	1
110	Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP) complex in first-trimester maternal serum screening for Down syndrome. Clinical Chemistry, 1997, 43, 2323-2332.	1.5	73
111	Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clinical Chemistry, 1997, 43, 1379-1385.	1.5	234
112	Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen. , 1997, 31, 84-90.		21
113	A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. Journal of Urology, 1996, 156, 350-354.	0.2	99
114	Structural investigation of the alphaâ€1â€antichymotrypsin: Prostateâ€specific antigen complex by comparative model building. Protein Science, 1996, 5, 836-851.	3.1	32
115	Epitope mapping of nine monoclonal antibodies against osteocalcin: Combinations into two-site assays affect both assay specificity and sample stability. Journal of Bone and Mineral Research, 1996, 11, 1165-1175.	3.1	33